MA38541A1 - Facteurs de transcription artificiels génétiquement modifiés pour pallier le piégeage endosomique - Google Patents
Facteurs de transcription artificiels génétiquement modifiés pour pallier le piégeage endosomiqueInfo
- Publication number
- MA38541A1 MA38541A1 MA38541A MA38541A MA38541A1 MA 38541 A1 MA38541 A1 MA 38541A1 MA 38541 A MA38541 A MA 38541A MA 38541 A MA38541 A MA 38541A MA 38541 A1 MA38541 A1 MA 38541A1
- Authority
- MA
- Morocco
- Prior art keywords
- artificial transcription
- genetically modified
- transcription factors
- protein
- zinc finger
- Prior art date
Links
- 102000040945 Transcription factor Human genes 0.000 title abstract 4
- 108091023040 Transcription factor Proteins 0.000 title abstract 4
- 108090000623 proteins and genes Proteins 0.000 abstract 3
- 101710185494 Zinc finger protein Proteins 0.000 abstract 2
- 102100023597 Zinc finger protein 816 Human genes 0.000 abstract 2
- 230000026683 transduction Effects 0.000 abstract 2
- 238000010361 transduction Methods 0.000 abstract 2
- 108091005804 Peptidases Proteins 0.000 abstract 1
- 239000004365 Protease Substances 0.000 abstract 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 230000002950 deficient Effects 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000001163 endosome Anatomy 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 239000012528 membrane Substances 0.000 abstract 1
- 230000030648 nucleus localization Effects 0.000 abstract 1
- 108020001580 protein domains Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 102000005962 receptors Human genes 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 230000008685 targeting Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/10—Fusion polypeptide containing a localisation/targetting motif containing a tag for extracellular membrane crossing, e.g. TAT or VP22
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Ophthalmology & Optometry (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Marine Sciences & Fisheries (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Medicinal Preparation (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
Abstract
L'invention concerne un facteur de transcription artificiel comprenant une protéine à doigt de zinc polydactyle ciblant spécifiquement un promoteur de gène, génétiquement modifié pour pallier le piégeage endosomique après transduction dans des cellules. Un tel facteur de transcription artificiel comprend une protéine à doigt de zinc polydactyle, condensée à un domaine de protéine d'inhibition ou d'activation, une séquence de localisation nucléaire, un domaine de transduction de protéine, et un site de reconnaissance de protéase spécifique à l'endosome. Ces facteurs de transcription artificiels transductibles sont particulièrement utiles pour le traitement de maladies provoquées ou modulées par des protéines réceptrices liées à la membrane, des protéines réceptrices nucléaires ou des produits de gènes haplo-insuffisants.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP13162197 | 2013-04-03 | ||
| PCT/EP2014/056589 WO2014161880A1 (fr) | 2013-04-03 | 2014-04-02 | Facteurs de transcription artificiels génétiquement modifiés pour pallier le piégeage endosomique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA38541A1 true MA38541A1 (fr) | 2017-02-28 |
Family
ID=48044672
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA38541A MA38541A1 (fr) | 2013-04-03 | 2015-10-21 | Facteurs de transcription artificiels génétiquement modifiés pour pallier le piégeage endosomique |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20160046682A1 (fr) |
| EP (1) | EP2981547A1 (fr) |
| JP (1) | JP2016515595A (fr) |
| KR (1) | KR20160002880A (fr) |
| CN (1) | CN105339386A (fr) |
| AR (1) | AR095982A1 (fr) |
| AU (1) | AU2014247130A1 (fr) |
| BR (1) | BR112015025283A2 (fr) |
| CA (1) | CA2908455A1 (fr) |
| EA (1) | EA201591593A1 (fr) |
| MA (1) | MA38541A1 (fr) |
| MX (1) | MX2015014021A (fr) |
| PH (1) | PH12015502421A1 (fr) |
| SG (1) | SG11201508057VA (fr) |
| TN (1) | TN2015000437A1 (fr) |
| TW (1) | TW201514202A (fr) |
| WO (1) | WO2014161880A1 (fr) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2016050934A1 (fr) * | 2014-10-02 | 2016-04-07 | Aliophtha Ag | Démêlage endosomal de facteurs de transcription artificiels |
| US11371023B2 (en) * | 2016-11-22 | 2022-06-28 | Wisconsin Alumni Research Foundation | Artificial transcription factors and uses thereof |
| CN106987599B (zh) * | 2017-03-28 | 2021-06-11 | 重庆医科大学 | 一种抑制人bcr-abl融合基因表达或导致人bcr-abl基因功能丧失的锌指核酸酶及其应用 |
| CN107632160B (zh) * | 2017-08-30 | 2019-04-30 | 福建师范大学 | Celsr3蛋白在制备肝癌术后预后评估试剂盒中的应用、肝癌预后评估试剂盒及方法 |
| SG11202004926WA (en) * | 2017-12-01 | 2020-06-29 | Encoded Therapeutics Inc | Engineered dna binding proteins |
| CN110108887B (zh) * | 2019-05-05 | 2022-01-28 | 深港产学研基地（北京大学香港科技大学深圳研修院） | Mff在心衰中的应用 |
| CN114375198A (zh) | 2019-05-16 | 2022-04-19 | 波士顿大学董事会 | 受调控的合成基因表达系统 |
| BR112021024055A2 (pt) | 2019-05-29 | 2022-02-08 | Encoded Therapeutics Inc | Composições e métodos para a regulação seletiva de gene |
| CN112695052A (zh) * | 2020-12-25 | 2021-04-23 | 华南农业大学 | 一种重组人糖皮质激素受体GRα-His蛋白及其表达和纯化方法 |
| CN113499335B (zh) * | 2021-07-13 | 2023-06-20 | 中国人民解放军军事科学院军事医学研究院 | 一种靶向自噬融合治疗神经退行性疾病的药物 |
| CN115703822A (zh) * | 2021-08-06 | 2023-02-17 | 中国科学院新疆生态与地理研究所 | BaZFP924蛋白及其相关生物材料与应用 |
| US20250230463A1 (en) * | 2021-08-26 | 2025-07-17 | Donald Danforth Plant Science Center | Engineering disease resistance by editing the epigenome |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050042603A1 (en) | 2003-07-01 | 2005-02-24 | Allele Biotechnology & Pharmaceuticals, Inc. | Compositions and methods for peptide-assisted transfection |
| WO2008063113A1 (fr) | 2006-11-20 | 2008-05-29 | Cepep Iii Ab | Peptides de pénétration cellulaire et construction les contenant constitués de 15 à 25 acides aminés de la protéine de suppression tumorale p14arf ou p19arf |
| US20110318830A1 (en) * | 2008-11-12 | 2011-12-29 | The Regents Of The University Of California | Compositions and methods for re-programming and re-differentiating cells |
| KR101095841B1 (ko) | 2009-02-19 | 2011-12-21 | 주식회사 나이벡 | 표적 선택적 세포／조직 투과기능 활성을 가지는 펩타이드 및 그 용도 |
-
2014
- 2014-04-01 AR ARP140101460A patent/AR095982A1/es unknown
- 2014-04-01 TW TW103112114A patent/TW201514202A/zh unknown
- 2014-04-02 WO PCT/EP2014/056589 patent/WO2014161880A1/fr not_active Ceased
- 2014-04-02 MX MX2015014021A patent/MX2015014021A/es unknown
- 2014-04-02 BR BR112015025283A patent/BR112015025283A2/pt not_active Application Discontinuation
- 2014-04-02 EP EP14714289.7A patent/EP2981547A1/fr not_active Withdrawn
- 2014-04-02 KR KR1020157031592A patent/KR20160002880A/ko not_active Withdrawn
- 2014-04-02 SG SG11201508057VA patent/SG11201508057VA/en unknown
- 2014-04-02 JP JP2016505804A patent/JP2016515595A/ja active Pending
- 2014-04-02 CA CA2908455A patent/CA2908455A1/fr not_active Abandoned
- 2014-04-02 CN CN201480031910.4A patent/CN105339386A/zh active Pending
- 2014-04-02 AU AU2014247130A patent/AU2014247130A1/en not_active Abandoned
- 2014-04-02 EA EA201591593A patent/EA201591593A1/ru unknown
- 2014-04-02 US US14/781,701 patent/US20160046682A1/en not_active Abandoned
-
2015
- 2015-09-28 TN TN2015000437A patent/TN2015000437A1/en unknown
- 2015-10-20 PH PH12015502421A patent/PH12015502421A1/en unknown
- 2015-10-21 MA MA38541A patent/MA38541A1/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2015014021A (es) | 2016-06-24 |
| CN105339386A (zh) | 2016-02-17 |
| TW201514202A (zh) | 2015-04-16 |
| PH12015502421A1 (en) | 2016-02-22 |
| BR112015025283A2 (pt) | 2017-10-10 |
| WO2014161880A1 (fr) | 2014-10-09 |
| AR095982A1 (es) | 2015-11-25 |
| EA201591593A1 (ru) | 2016-04-29 |
| SG11201508057VA (en) | 2015-10-29 |
| US20160046682A1 (en) | 2016-02-18 |
| JP2016515595A (ja) | 2016-05-30 |
| TN2015000437A1 (en) | 2017-01-03 |
| AU2014247130A1 (en) | 2015-10-22 |
| EP2981547A1 (fr) | 2016-02-10 |
| KR20160002880A (ko) | 2016-01-08 |
| CA2908455A1 (fr) | 2014-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA38541A1 (fr) | Facteurs de transcription artificiels génétiquement modifiés pour pallier le piégeage endosomique | |
| MX2019006045A (es) | Proteinas triespecificas dirigidas a psma y metodos de uso. | |
| EA201792573A1 (ru) | Триспецифические связанные белки и способы их применения | |
| EP4144372A3 (fr) | Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation | |
| MA40972B1 (fr) | Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t ciblant folr1 et cd3 | |
| MX2016015834A (es) | Receptores quiméricos de antigeno que tienen como diana a cd-19. | |
| EA201790288A1 (ru) | Анти-ctla4 моноклональное антитело или его антигенсвязывающий фрагмент, фармацевтическая композиция и применение | |
| SG11201806502UA (en) | Conjugate of therapeutic enzymes | |
| EP4406604A3 (fr) | Protéines de fusion immunomodulatrices et leurs utilisations | |
| EP3939606A3 (fr) | Composés et procédés améliorés permettant de supprimer des réponses immunitaires à des agents thérapeutiques | |
| BR112017007773A2 (pt) | novos peptídeos imunogênicos | |
| UA117045C2 (uk) | Гібридний білок для пригнічення ангіогенезу або судинного росту та його застосування | |
| MA34722B1 (fr) | Méthodes et compositions pour l'immunothérapie de maladies neurales | |
| BR112019000693A2 (pt) | composições de muc1- car e métodos para uso | |
| WO2019098763A3 (fr) | ANTICORPS ANTI-α-SYNUCLÉINE ET LEURS UTILISATIONS | |
| NZ774126A (en) | Spd-1 variant - fc fusion proteins | |
| EA201692025A1 (ru) | Доставка белков, осуществляемая на основе бактерий | |
| ECSP20083339A (es) | Proteínas inmunodominantes y fragmentos en esclerosis múltiple | |
| PH12019502075A1 (en) | A liquid formulation of anti-tnf alpha antibody | |
| EA202090084A1 (ru) | Новый терапевтический ферментный слитый белок и его применение | |
| MX2018003445A (es) | Expresion de proteinas que contienen fc. | |
| AR106556A1 (es) | Anticuerpos de un solo dominio dirigidos contra antígenos extracelulares | |
| BR112021026364A2 (pt) | Antígenos de câncer e métodos | |
| BR112022000020A2 (pt) | Antígenos de câncer inovadores e métodos | |
| NZ731491A (en) | Cd83 binding proteins and uses thereof |